George Farmer
Stock Analyst at Scotiabank
(1.76)
# 3,246
Out of 4,962 analysts
70
Total ratings
34.21%
Success rate
-9.01%
Average return
Main Sectors:
Top Industries:
Stocks Rated by George Farmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMEA Biomea Fusion | Maintains: Sector Outperform | $30 → $10 | $1.81 | +452.49% | 4 | Aug 6, 2025 | |
| ACLX Arcellx | Maintains: Sector Outperform | $93 → $133 | $68.49 | +94.19% | 3 | Jul 31, 2025 | |
| INMB INmune Bio | Downgrades: Sector Underperform | $23 → $0.6 | $2.24 | -73.15% | 3 | Jul 1, 2025 | |
| URGN UroGen Pharma | Maintains: Sector Outperform | $23 → $47 | $18.51 | +153.92% | 1 | Jun 13, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Sector Perform | $16 → $17 | $15.61 | +8.90% | 4 | May 6, 2025 | |
| TARA Protara Therapeutics | Initiates: Sector Outperform | $12 | $3.07 | +290.88% | 1 | Apr 16, 2025 | |
| TPST Tempest Therapeutics | Downgrades: Sector Perform | $91 → $9 | $10.56 | -14.77% | 4 | Apr 10, 2025 | |
| ADAP Adaptimmune Therapeutics | Maintains: Sector Outperform | $3.15 → $1.4 | $0.06 | +2,206.43% | 2 | Mar 21, 2025 | |
| JANX Janux Therapeutics | Maintains: Sector Perform | $62 → $41 | $23.01 | +78.18% | 4 | Feb 28, 2025 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Sector Outperform | $47 → $52 | $24.70 | +110.53% | 4 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $78 → $80 | $58.52 | +36.72% | 8 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $244 → $224 | $136.39 | +64.23% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $102 | $25.83 | +294.89% | 1 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $18 → $10 | $7.62 | +31.23% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $439 → $715 | $676.57 | +5.68% | 5 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $20 → $23 | $6.52 | +252.76% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $20 | $3.52 | +468.18% | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $70 → $76 | $34.61 | +119.59% | 4 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $13 | $2.54 | +411.81% | 1 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $109 | $25.36 | +329.90% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $94 → $87 | $84.75 | +2.65% | 5 | Nov 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $2.54 | +1,201.78% | 1 | Oct 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $0.88 | +4,462.04% | 1 | Jul 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $20 → $27 | $37.93 | -28.82% | 3 | May 6, 2020 |
Biomea Fusion
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $30 → $10
Current: $1.81
Upside: +452.49%
Arcellx
Jul 31, 2025
Maintains: Sector Outperform
Price Target: $93 → $133
Current: $68.49
Upside: +94.19%
INmune Bio
Jul 1, 2025
Downgrades: Sector Underperform
Price Target: $23 → $0.6
Current: $2.24
Upside: -73.15%
UroGen Pharma
Jun 13, 2025
Maintains: Sector Outperform
Price Target: $23 → $47
Current: $18.51
Upside: +153.92%
Syndax Pharmaceuticals
May 6, 2025
Maintains: Sector Perform
Price Target: $16 → $17
Current: $15.61
Upside: +8.90%
Protara Therapeutics
Apr 16, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $3.07
Upside: +290.88%
Tempest Therapeutics
Apr 10, 2025
Downgrades: Sector Perform
Price Target: $91 → $9
Current: $10.56
Upside: -14.77%
Adaptimmune Therapeutics
Mar 21, 2025
Maintains: Sector Outperform
Price Target: $3.15 → $1.4
Current: $0.06
Upside: +2,206.43%
Janux Therapeutics
Feb 28, 2025
Maintains: Sector Perform
Price Target: $62 → $41
Current: $23.01
Upside: +78.18%
NewAmsterdam Pharma Company
Feb 27, 2025
Maintains: Sector Outperform
Price Target: $47 → $52
Current: $24.70
Upside: +110.53%
Feb 20, 2025
Maintains: Sector Perform
Price Target: $78 → $80
Current: $58.52
Upside: +36.72%
Feb 13, 2025
Maintains: Sector Outperform
Price Target: $244 → $224
Current: $136.39
Upside: +64.23%
Feb 13, 2025
Initiates: Sector Outperform
Price Target: $102
Current: $25.83
Upside: +294.89%
Jan 8, 2025
Maintains: Sector Perform
Price Target: $18 → $10
Current: $7.62
Upside: +31.23%
Nov 5, 2024
Upgrades: Sector Outperform
Price Target: $439 → $715
Current: $676.57
Upside: +5.68%
Oct 18, 2024
Maintains: Sector Outperform
Price Target: $20 → $23
Current: $6.52
Upside: +252.76%
Sep 30, 2024
Initiates: Sector Outperform
Price Target: $20
Current: $3.52
Upside: +468.18%
Aug 12, 2024
Maintains: Sector Outperform
Price Target: $70 → $76
Current: $34.61
Upside: +119.59%
Mar 14, 2024
Initiates: Sector Outperform
Price Target: $13
Current: $2.54
Upside: +411.81%
Nov 17, 2020
Downgrades: Market Perform
Price Target: $109
Current: $25.36
Upside: +329.90%
Nov 6, 2020
Maintains: Market Perform
Price Target: $94 → $87
Current: $84.75
Upside: +2.65%
Oct 27, 2020
Initiates: Outperform
Price Target: $33
Current: $2.54
Upside: +1,201.78%
Jul 20, 2020
Initiates: Outperform
Price Target: $40
Current: $0.88
Upside: +4,462.04%
May 6, 2020
Maintains: Market Perform
Price Target: $20 → $27
Current: $37.93
Upside: -28.82%